Literature DB >> 17680465

Sudden hearing loss in chronic hepatitis C patient suffering from Turner syndrome, treated with pegylated interferon and ribavirin.

Anna Piekarska1, Magdalena Jozefowicz-Korczynska, Kamila Wojcik, Ewa Berkan.   

Abstract

Sudden hearing loss is a very rare complication of interferon-alpha treatment. At this time, hearing loss in patients treated with pegylated interferon and ribavirin has only been described in two reports. We present a case of a 27-year-old patient who was diagnosed with Turner syndrome, treated for hepatitis C with pegylated interferon and ribavirin, and suffered from hearing loss during the 10th week of treatment. Audiometric examination revealed a bilateral sensorineural hearing loss (SNHL). Auditory brainstem response (ABR) measures confirmed the diagnosis. We decided to comply with the patient's request to continue therapy, which only led to slight further deterioration of the patient's hearing ability. However, 18 months after the end of therapy a follow-up audiometric examination disclosed a bilateral SNHL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680465     DOI: 10.1080/14992020701261413

Source DB:  PubMed          Journal:  Int J Audiol        ISSN: 1499-2027            Impact factor:   2.117


  5 in total

1.  Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.

Authors:  Savita Jain; Vandana Midha; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2011-09

2.  Effect of interferon treatment on hearing of patients with chronic hepatitis C.

Authors:  Abdulrahman Hagr; Dima Jamjoom; Faisal M Sanai; Waleed Al Hamoudi; Ayman A Abdo; Ahmed Al-Arfaj
Journal:  Saudi J Gastroenterol       Date:  2011 Mar-Apr       Impact factor: 2.485

3.  A case of hearing loss associated with pegylated interferon and ribavirin treatment ameliorated by prednisone.

Authors:  Vu Le; Ted Bader; Javid Fazili
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

Review 4.  A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.

Authors:  Christine Little; Maura K Cosetti
Journal:  Laryngoscope       Date:  2021-01-27       Impact factor: 2.970

5.  Assessment of auditory functions in chronic hepatitis C patients treated by sofosbuvir.

Authors:  Elshahat Ibrahem Ismail; Ashraf Elsayed Morgan; Raghda Elsayed Farag
Journal:  J Otol       Date:  2017-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.